The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Vaccines can be highly effective tools in combating antimicrobial resistance as they reduce infections caused by antibiotic-resistant bacteria and antibiotic consumption associated with disease. This Review looks at vaccine candidates that are in development against pathogens on the 2017 WHO bacterial priority pathogen list, in addition to Clostridioides difficile and Mycobacterium tuberculosis. There were 94 active preclinical vaccine candidates and 61 active development vaccine candidates. We classified the included pathogens into the following four groups: Group A consists of pathogens for which vaccines already exist-ie, Salmonella enterica serotype Typhi, Streptococcus pneumoniae, Haemophilus influenzae type b, and M tuberculosis. Group B consists of pathogens with vaccines in advanced clinical development-ie, extra-intestinal pathogenic Escherichia coli, Salmonella enterica serotype Paratyphi A, Neisseria gonorrhoeae, and C difficile. Group C consists of pathogens with vaccines in early phases of clinical development-ie, enterotoxigenic E coli, Klebsiella pneumoniae, non-typhoidal Salmonella, Shigella spp, and Campylobacter spp. Finally, group D includes pathogens with either no candidates in clinical development or low development feasibility-ie, Pseudomonas aeruginosa, Acinetobacter baumannii, Staphylococcus aureus, Helicobacter pylori, Enterococcus faecium, and Enterobacter spp. Vaccines are already important tools in reducing antimicrobial resistance and future development will provide further opportunities to optimise the use of vaccines against resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
The role of nasal carriage in Staphylococcus aureus infections
Wertheim, H. F., Melles, D. C., Vos, M. C., van Leeuwen, W., van Belkum, A., Verbrugh, H. A., & Nouwen, J. L. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70295-4 · Cited by 2,685
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Stanaway, J. D., Parisi, A., Sarkar, K., Blacker, B. F., Reiner, R. C., Hay, S. I., Nixon, M. R., Dolecek, C., James, S. L., Mokdad, A. H., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30418-9 · Cited by 645
Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Tait, D. R., Hatherill, M., Van Der Meeren, O., Ginsberg, A. M., Van Brakel, E., Salaun, B., Scriba, T. J., Akite, E. J., Ayles, H. M., Bollaerts, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909953 · Cited by 605
mRNA vaccines manufacturing: challenges and bottlenecks
Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., & Marques, M. P. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.038 · Cited by 545
Where does a Staphylococcus aureus vaccine stand?
Fowler, V. G., & Proctor, R. A. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12570 · Cited by 241
Cited by
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
Multidrug-resistant Gram-negative bacterial infections
Macesic, N., Uhlemann, A.-C., & Peleg, A. Y. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02081-6 · Cited by 315
Naghavi, M., Mestrovic, T., Gray, A., Gershberg Hayoon, A., Swetschinski, L. R., Robles Aguilar, G., Davis Weaver, N., Ikuta, K. S., Chung, E., Wool, E. E., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00158-0 · Cited by 311
Laxminarayan, R., Impalli, I., Rangarajan, R., Cohn, J., Ramjeet, K., Trainor, B. W., Strathdee, S., Sumpradit, N., Berman, D., Wertheim, H., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00878-x · Cited by 111
Metadata
- Authors
- Frost, I., Sati, H., Garcia-Vello, P., Hasso-Agopsowicz, M., Lienhardt, C., Gigante, V., & Beyer, P.
- Venue
- The Lancet Microbe
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 4
- Issue
- 2
- Pages
- e113-e125
- ISSN
- 2666-5247 (ISSN-L)
- OpenAlex
- W4311471854
- Cited by
- 193
- References
- 7
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline. https://app.cochat.ai/papers/10.1016/s2666-5247(22)00303-2
- The paper
- Frost, I., Sati, H., Garcia-Vello, P., Hasso-Agopsowicz, M., Lienhardt, C., Gigante, V., & Beyer, P. (2023). The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline. The Lancet Microbe. https://doi.org/10.1016/s2666-5247(22)00303-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.